UPDATE: BTIG Starts BioAtla Inc. (BCAB) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. SPY
2. CRWV
3. SLGN
4. EYPT
5. SLN
6. PNB:IN
7. LTM:IN
8. CHRD
9. IRON
10. MANE

Go back to UPDATE: BTIG Starts BioAtla Inc. (BCAB) at Buy

UPDATE: Credit Suisse Starts BioAtla Inc. (BCAB) at Outperform

January 11, 2021 5:01 AM EST

(Updated - January 11, 2021 6:23 AM EST)

Credit Suisse analyst Tiago Fauth initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Outperform rating and a price target of $49.00.

The analyst comments "The companys two lead proprietary programs targeting AXL (BA3011) and ROR2 (BA3021) are antibody-drug conjugates (ADC) designed with BCABs proprietary conditionally active biologics (CAB) technology. CAB molecules have... More

UPDATE: Jefferies Starts BioAtla Inc. (BCAB) at Buy Ahead of Two Separate Phase 2 Readouts

January 11, 2021 4:43 AM EST

(Updated - January 11, 2021 8:52 AM EST)

Jefferies analyst Biren Amin initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Buy rating and a price target of $51.00 ahead of Ph2 interim readouts in H2' 21. Jefferies was joint book-running manager in BCAB's... More

JPMorgan Starts BioAtla Inc. (BCAB) at Overweight

January 11, 2021 4:42 AM EST

JPMorgan initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Overweight rating and a price target of $45.00.


For an analyst ratings summary and ratings history on BioAtla Inc. click here. For more ratings news on BioAtla Inc. click here.


Shares of BioAtla Inc. closed at $38.25 yesterday.

... More